Renaissance Capital logo

Vaccinex Priced, Nasdaq: VCNX

Developing antibody therapies to combat cancer and neurological diseases.

Industry: Health Care

First Day Return: -5.2%

Industry: Health Care

We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. We believe we are the leader in the field of SEMA4D biology, and that we are the only company targeting it as a potential treatment for cancer, neurodegenerative diseases, or autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the migration of immune and inflammatory cells to sites of injury, cancer or infection. We are leveraging our SEMA4D antibody platform to develop our lead product candidate VX15 to treat NSCLC and Huntington's disease, which we believe utilizes novel mechanisms of action. Additionally, in coordination with us, one investigator is studying VX15 in osteosarcoma and another is expected to study VX15 in melanoma. We have developed multiple proprietary platform technologies and are developing product candidates to address serious diseases or conditions that have a substantial impact on day-to-day functioning and for which treatment is not addressed adequately by available therapies.
more less
IPO Data
IPO File Date 07/09/2018
Offer Price $12.00
Price Range $12.00 - $15.00
Offer Shares (mm) 3.3
Deal Size ($mm) $40
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 08/09/2018
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $40
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Rochester, NY, United States
Founded 2001
Employees at IPO 43
Website www.vaccinex.com

Vaccinex (VCNX) Performance